Alberta Court: Paxil Birth Defect Settlement Approval Finalized

• The Alberta Court of King's Bench approved a $7.5 million settlement distribution in a national class action concerning GlaxoSmithKline's antidepressant Paxil.
• The lawsuit alleged Paxil caused congenital malformations in children whose mothers took the drug during pregnancy.
• A prior contingency fee agreement with original counsel, Merchant Law Group, was declared invalid by the court.
• The court ruled that claims administration costs must be paid from legal fees, not from class members' compensation.
• Eligible claimants with cardiovascular defects must affirm by affidavit they have not received prior compensation for the same defect in other provincial class actions.

The court mandated that the costs associated with the claims administrator, the claims officer, and any honorarium should be deducted from the legal fees awarded, rather than diminishing the compensation received by class members.

The Alberta Court of King's Bench has formally approved the distribution plan for a significant $7.5 million settlement in a national class action against GlaxoSmithKline (GSK). This `Alberta Paxil birth defect settlement approval` addresses claims that the antidepressant Paxil caused birth defects in children whose mothers used the medication during pregnancy. Justice Janice Ashcroft issued two distinct orders on September 8, encompassing both the allocation of the settlement fund and the determination of legal fees for the plaintiff-side law firms involved.

The court has directed the claims administrator to prioritize completing all payments by November 6, ensuring timely compensation for eligible claimants. This `GlaxoSmithKline Paxil class action Canada` originated in 2012, when Fiona Singh and her son, Muzaffar Hussain, initiated legal proceedings against three GSK entities. Their lawsuit specifically alleged that Paxil and Paxil CR, both selective serotonin reuptake inhibitor (SSRI) antidepressants, heightened the risk of `Paxil congenital malformations lawsuit` in infants born to women who consumed these drugs while pregnant. The $7.5 million settlement itself had received initial approval on September 24, 2024.

The path to this `Singh v. GlaxoSmithKline Inc. settlement` was marked by a contentious dispute over legal fees, which significantly delayed the resolution of cost applications. The plaintiff, Fiona Singh, changed legal representation in 2019, moving from Merchant Law Group to a consortium of other firms. This transition led to disagreements regarding fee entitlements. In a key ruling in March 2025, Justice Jane Sidnell of the `Alberta Court of King's Bench Paxil` proceedings declared a 2018 contingency fee agreement with Merchant Law invalid. Despite its invalidity, the court utilized this agreement as a benchmark to assess reasonable fee expectations.

Further, Justice Sidnell mandated that the costs associated with the claims administrator, the claims officer, and any honorarium should be deducted from the legal fees awarded, rather than diminishing the compensation received by class members. In June 2025, the court declined to award costs for the March proceedings to any party, citing that the conduct of those involved had unnecessarily prolonged the legal process. The court emphasized that internal disputes among counsel, including ongoing litigation in Ontario, should not have impacted the Alberta case.

The `class action settlement distribution Alberta` outlines specific requirements for claimants. Any eligible individual whose approved claim includes a structural cardiovascular defect must submit an affidavit by September 29, confirming that they have not received compensation for the same defect through similar class proceedings in other Canadian provinces. Claimants who have already been compensated elsewhere for a heart defect will be ineligible for payment for that specific condition in the Alberta action, though they may still qualify for compensation related to other approved malformations. This stipulation reflects a prior Paxil litigation in British Columbia, which concluded with a $6.2 million settlement in 2017.

Beyond individual claimants, the distribution order allocates $525,000 to provincial and territorial health insurers. The legal fees for the consortium of plaintiff firms totaled $1,157,143.93, plus $57,856.70 in GST, with Napoli Shkolnik Canada receiving $537,961.62 and Guardian Law Group receiving $59,772.40 of the class counsel fees, alongside approximately $560,000 plus GST in separate "Lawyers' Fees" tied to individual claimants. Merchant Law Group LLP, the original counsel, was awarded $597,724.02 plus $29,886.20 in GST as its share of class counsel fees. Jonathan Denis of Guardian Law Group LLP, representing several claimants, expressed satisfaction with the outcome, stating that such cases should motivate pharmaceutical manufacturers to conduct more thorough product testing before market release, thereby preventing similar situations.

Lawyers involved in class actions should note the court's approach to settlement distribution, particularly the requirement for claimant affidavits regarding prior compensation, and the precedent set regarding the invalidation of contingency fee agreements and the allocation of claims administration costs from legal fees. For pharmaceutical compliance officers, this case underscores the substantial liability risks associated with product safety and the importance of rigorous testing.

Source: Original reporting via Canadian Legal Newswire.